<img src="https://ml.globenewswire.com/Resource/Download/24d1d851-9075-4d6e-b22c-0c23a5ef0b36?size=2" nborder="0" align="left" hspace="5" vspace="5" title="ANI logo.png" alt="ANI Pharmaceuticals, Inc."/>PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results. To view the webcast, please click <a href="https://www.globenewswire.com/Tracker?data=3xOBDl5VgAiHBKXeRodLkYS51B19ubBH54nDa4O_u_Z9VQyTkV_0bmKTJpVCA5evW5PLp1wuh-BDmbjuiykQs8L8DDC8dhJaDqi0fr589Hw=" rel="nofollow" target="_blank" title="here">here</a>. Links to access the webcast and conference call will also be available on the “Events &amp; Presentations” page of the Company’s website at <a href="https://www.globenewswire.com/Tracker?data=ZoSq3nBLYTgMBXhJlXcfI9QSEYhrxkiT64dauRvhr9VUBQ8T63H7EkL6AQAvcHcCpxVLQZaWwcG4_lsmCKd60V-vsE7uWCuFqLGVcCRuB2scOHQnjs3HCfDMuScnlmdf-t4broWfjOjVACxHOzvYAERtIcsGOEoCvIGX4skv7dkx55YYTFl10CcnPGS65je1M8TTCtVsElxypdumhazFKlQD71kEClzbxal7ZVeiXiR_X9OamIXUCxagjHVA-nE3h3-X1kZLoYo9SY4TUEu9floJbM1_uQEIcsyZGbHx8OzSp6mP4241UTrZyXmvsryi" rel="nofollow" target="_blank" title="">https://www.anipharmaceuticals.com</a>, under the “Investors” section. A replay of the event will remain accessible for up to one year. About ANI ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&amp;D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=ZoSq3nBLYTgMBXhJlXcfI9QSEYhrxkiT64dauRvhr9Xm5hxCRcCnjOG0c203_i0ABgol5i8TXChN3_KXUiSGlBOd6mywODWFmWayRvST3Tf3rDvRS4ak52LjbdwUajndwnhv08wnNOoFjG_Qjbryqg==" rel="nofollow" target="_blank" title="">https://www.anipharmaceuticals.com.</a> Investor Relations: Irina Koffler, Vice President, Investor Relations T: 917-734-7387 E: Irina.koffler@anipharmaceuticals.com Media Relations: Argot Partners T: 212-600-1494 E: ani@argotpartners.com SOURCE: ANI Pharmaceuticals, Inc. <img alt="" src='https://ml.globenewswire.com/media/M2Y3MGI5MDYtOTE4Yi00MWRmLTk5NzktZGQ5NGQ1Yzc2ODYyLTEwMzA4MzMtMjAyNi0wNy0yNC1lbg==/tiny/ANI-Pharmaceuticals-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn